Subjective cognitive decline predicts future dementia risk, study finds

SINGAPORE — Treatment with osimertinib (Tagrisso) plus chemotherapy reduced the risk of disease progression or death by 38% compared with osimertinib monotherapy in patients with

Patients with beta-thalassemia major (also known as Cooley’s anemia) have a reduction or absence of beta protein in their hemoglobin, resulting in severe anemia, which